Advanced search
Publication Cover
HIV Clinical Trials Volume 10, 2009 - Issue 1
Submit an article Journal homepage
100
Views
11
CrossRef citations to date
0
Altmetric
Brief reports

Prevalence of HLA-B*5701 in HIV-Infected Patients in Spain (Results of the EPI Study)

J. ArrizabalagaInfectious Diseases Unit H. Donostia, San Sebastian, Spain
,
F. Rodriguez-AlcántaraMedical Department GlaxoSmithKline, Tres Cantos, Madrid, SpainCorrespondence[email protected]
,
J.L. CastañerImmunology Unit H. Ramón y Cajal, Madrid, Spain
,
A. OcampoInternal Medicine-HIV Unit H. Xeral de Vigo, Spain
,
D. PodzamczerInfectious Diseases Unit H. Bellvitge, Barcelona, Spain
,
F. PulidoHIV Unit H. Doce de Octubre, Madrid, Spain
,
M. RieraInfectious Diseases Unit H. Son Dureta, P. Mallorca, Spain
,
J. SanzInfectious Diseases Unit H. La Princesa, Madrid, Spain
,
M. Pascual-BernaldezMedical Department GlaxoSmithKline, Tres Cantos, Madrid, Spain
,
R. Dal-ReMedical Department GlaxoSmithKline, Tres Cantos, Madrid, Spain
& the EPI109839 Study Group* show all
Pages 48-51 | Published online: 06 Jan 2015

REFERENCES

  • Hetherington S, McGuirk S, Powell G, et al. Hypersen-sitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001;23: 1603–1614.
  • Hernandez JE, Cutrell A, Edwards M, et al. Clinical risk factors of hypersensitivity reactions to abacavir: Retro-spective analysis of over 8000 subjects receiving abacavir in 34 clinical trials [abstract]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14–17, 2003; Chicago, IL. Washington, DC: American Society for Microbiology, 2003:339.
  • Peyriere H, Nicholas J, Sliffer M, et al. Hypersensitivity related to abacavir in two members of a family. Ann Phar-macother 200135: 1291–1292.
  • Symonds W, Cutrell A, Edwards M, et al. Risk factors analysis of hypersensitivity reactions to Abacavir. Clin Ther 2002;24:565–573.
  • Melia! S, Nolan D, Witt C, et al. Association between pres-ence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hyper-sensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet. 2002;359:727–732.
  • Hetherington S, Hughes AR, Mosteller M, et al. Generic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121–1122.
  • Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and hoplotypic Hsp7O-Hom variant. Proc Nat! Acad Sci USA. 2004;101:4180–4185.
  • Rauch A, Nolan D, Martin A, et al. Perspective genetic screening decreases the incidence of abacavir hypersensi-tivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43:99–102.
  • Reeves I, Churchill D, Fisher M. Screening for HLA-B5701 reduces the frequency of abacavir hypersensitivity [abstract]. Antivir Ther 2006;11(Suppl):L11.
  • Zucman D, Truchis P, Majerholc C, et al. Prospective screening for human leukocyte antigen B*5701 avoids abacavir hypersensitivity reaction in the ethically mixed French HIV population. J Acquir Immune Defic Syndr. 2007;45(1)1–3.
  • Melia! S, Philips E, Carosi G, et al. HLA-B*5701 screen-ing for hypersensitivity to Abacavir. New Engl J Med. 2008;358:568–579.
  • Nolan D, Gaudieri S, Melia S. Pharmacogenetics: A practi-cal role in predicting antiretroviral drug toxicity? J HIV Ther 2003;8: 36–41.
  • Martin AM, Nolan D, Melia! S. HLA-B*5701 typing by sequence-specific amplification: Validation and com-parison with sequence-based typing. Tissue Antigens. 2005;65:571–574.
  • Ministerio Sanidad y Consumo, Plan Nacional del Sida, Vigilancia Epidemiológica available, Infección por VIH. Available at: http://www.isciii.es/htdocs/centros/epidemiologia/epi_sida.jsp.
  • Newcombe RG. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med. 1998;17:857–872.
  • Molina JM, et al. A prospective epidemiological study to determine the prevalence of HLA-B*5701 in French HIV-1 infected patients: PEPI study. In: Program and abstracts of the 11th European AIDS Conference; October 24–27, 2007; Madrid, Spain. Abstract p18.1/01.
  • Orkin C. et al. Prospective epidemiological study of the prevalence of HLA-B*5701 in HIV infected UK subjects. In: Program and abstracts of the 11th European AIDS Confer-ence EACS; October 24–27, 2007; Madrid, Spain. Abstract p4.4/02.
  • Hughes DA, Viler FJ, Ward CH, et al. Cost-effectiveness analysis of HLA-B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004;14: 335–342.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.